Differential expression of lipid peroxidation and total antioxidant status in Indian patients with cardiovascular and cerebrovascular disease

Can J Physiol Pharmacol. 2014 Jul;92(7):592-7. doi: 10.1139/cjpp-2013-0481. Epub 2014 Apr 7.

Abstract

Data from studies examining lipid peroxidation as a mechanism involved with hyperhomocysteinemia (HHcy)-induced vascular remodeling in patients with occlusive vascular disease have been contradictory. It has not yet been studied in Indians within the context of atherogenesis. Therefore, we measured the levels of homocysteine (Hcy), malondialdehyde (MDA) as a measure of lipid peroxides (LPOs), and total antioxidant status (TAS) in the serum of 167 patients with occlusive vascular disease [coronary artery disease (CAD) = 43; cerebrovascular disease (CVD) = 82; peripheral vascular disease (PVD) = 42]. Each of these groups was further divided into groups of individuals with or without HHcy. In the case of CAD and CVD, patients with HHcy had significantly higher LPOs than those without HHcy (p = 0.009, 0.001, respectively). TAS was significantly lower in CVD patients with HHcy than in those without (p = 0.014). In patients with CAD or CVD, Hcy directly correlated with LPOs (p = 0.002, 0.001, respectively). Lipid peroxidation is a significant mechanism in HHcy-induced vascular remodeling in CAD and CVD, but not in PVD, probably because it is not relevant in thrombosis (38 of 42 patients of PVD had deep-vein thrombosis). To explain the significantly lower TAS in CVD, we hypothesized that CVD patients present very early with grave symptoms, whereas CAD and PVD occur over a longer period of time. Therefore, when CVD presents, TAS is still overwhelmed by HHcy-induced oxidative stress. Hence, adjuvant therapy with antioxidants would benefit patients with CVD.

Keywords: hyperhomocysteinemia; hyperhomocystéinémie; lipid peroxides; maladie vasculaire; malondialdehyde; malondialdéhyde; peroxydes lipidiques; total antioxidant status; vascular disease; état antioxydant total.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antioxidants / metabolism*
  • Cardiovascular Diseases / complications
  • Cardiovascular Diseases / metabolism*
  • Cerebrovascular Disorders / complications
  • Cerebrovascular Disorders / metabolism*
  • Humans
  • Hyperhomocysteinemia / complications
  • Hyperhomocysteinemia / metabolism
  • India
  • Lipid Peroxidation*
  • Oxidative Stress

Substances

  • Antioxidants

Supplementary concepts

  • Homocysteinemia